These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9257761)

  • 41. Population pharmacokinetics of cefepime in neonates with severe nosocomial infections.
    Lima-Rogel V; Medina-Rojas EL; Del Carmen Milán-Segovia R; Noyola DE; Nieto-Aguirre K; López-Delarosa A; Romano-Moreno S
    J Clin Pharm Ther; 2008 Jun; 33(3):295-306. PubMed ID: 18452417
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of the novel cephalosporin cefepime (BMY-28142) in rats and monkeys.
    Forgue ST; Shyu WC; Gleason CR; Pittman KA; Barbhaiya RH
    Antimicrob Agents Chemother; 1987 May; 31(5):799-804. PubMed ID: 3606078
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of rapacuronium in infants and children with intravenous and intramuscular administration.
    Reynolds LM; Infosino A; Brown R; Hsu J; Fisher DM
    Anesthesiology; 2000 Feb; 92(2):376-86. PubMed ID: 10691223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance.
    Conil JM; Georges B; Lavit M; Seguin T; Tack I; Samii K; Chabanon G; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2007 Oct; 45(10):529-38. PubMed ID: 17966838
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses.
    Barbhaiya RH; Forgue ST; Gleason CR; Knupp CA; Pittman KA; Weidler DJ; Martin RR
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1118-22. PubMed ID: 2203303
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.
    Malone RS; Fish DN; Abraham E; Teitelbaum I
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3148-55. PubMed ID: 11600370
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of plasma exchange on the disposition of the fourth generation cephalosporin cefepime.
    Ibrahim RB; Liu CY; Cronin SM; Murphy BC; Cha R; Swerdlow P; Avila T; Smith ST; Lewis RA; Edwards DJ
    J Oncol Pharm Pract; 2009 Dec; 15(4):217-22. PubMed ID: 19304881
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety, tolerance and pharmacokinetics of cefpirome administered intramuscularly to healthy subjects.
    Meyer BH; Muller FO; Luus HG; Drees B; Röthig HJ; Badian M; Eckert HG
    J Antimicrob Chemother; 1992 Apr; 29 Suppl A():63-70. PubMed ID: 1601759
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoeitic Cell Transplantation.
    Whited L; Grove M; Rose D; Rhodes NJ; Scheetz MH; O'Donnell JN; Neeb J; Thoele K; Jones DR; Lowe C; Moore D; Kiel PJ
    Pharmacotherapy; 2016 Sep; 36(9):1003-10. PubMed ID: 27496678
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma, urine and skin pharmacokinetics of cefepime in burns patients.
    Sampol E; Jacquet A; Viggiano M; Bernini V; Manelli JC; Lacarelle B; Durand A
    J Antimicrob Chemother; 2000 Aug; 46(2):315-7. PubMed ID: 10933661
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pancreatic concentrations of cefepime in experimental necrotizing pancreatitis.
    Papagoras D; Giamarellos-Bourboulis EJ; Kanara M; Douridas G; Paraskevopoulos I; Antzaklis G; Karayannacos P; Giamarellou H
    J Chemother; 2003 Feb; 15(1):43-6. PubMed ID: 12678413
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics and bioavailability of cefquinome in healthy piglets.
    Li XB; Wu WX; Su D; Wang ZJ; Jiang HY; Shen JZ
    J Vet Pharmacol Ther; 2008 Dec; 31(6):523-7. PubMed ID: 19000274
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics, intramuscular bioavailability and tissue residue profiles of ceftazidime in a rabbit model.
    Abd El-Aty AM; Goudah A; Abo El Sooud K
    Dtsch Tierarztl Wochenschr; 2001 Apr; 108(4):168-71. PubMed ID: 11370478
    [TBL] [Abstract][Full Text] [Related]  

  • 55. DISPOSITION OF CEFTIOFUR AND ITS ACTIVE METABOLITES IN FALLOW DEER (DAMA DAMA) FOLLOWING SINGLE-DOSE INTRAVENOUS AND INTRAMUSCULAR ADMINISTRATION.
    Kottwitz J; Blue-McLendon A; Monarski C; Jensen J; Boothe D
    J Zoo Wildl Med; 2015 Jun; 46(2):255-61. PubMed ID: 26056876
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion.
    Burgess DS; Hastings RW; Hardin TC
    Clin Ther; 2000 Jan; 22(1):66-75. PubMed ID: 10688391
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Once-daily cefepime versus ceftriaxone for nursing home-acquired pneumonia.
    Paladino JA; Eubanks DA; Adelman MH; Schentag JJ
    J Am Geriatr Soc; 2007 May; 55(5):651-7. PubMed ID: 17493183
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of piritramide in newborns, infants and young children in intensive care units.
    Müller C; Kremer W; Harlfinger S; Doroshyenko O; Jetter A; Hering F; Hünseler C; Roth B; Theisohn M
    Eur J Pediatr; 2006 Apr; 165(4):229-39. PubMed ID: 16496200
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cefepime in intensive care unit patients: validation of a population pharmacokinetic approach and influence of covariables.
    Georges B; Conil JM; Seguin T; Dieye E; Cougot P; Decun JF; Lavit M; Samii K; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2008 Apr; 46(4):157-64. PubMed ID: 18397688
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa.
    Tam VH; Louie A; Lomaestro BM; Drusano GL
    Pharmacotherapy; 2003 Mar; 23(3):291-5. PubMed ID: 12627925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.